Asthma snip from Quarterly...
"In addition to demonstrating efficacy in pre-clinical models of GvHD and critical limb ischaemia, the Company now has compelling data for its Cymerus™ MSCs in an animal model of asthma. In a study conducted under the supervision of Associate Professor Chrishan Samuel and Dr Simon Royce at Monash University, intravenous administration of Cynata’s MSCs in animals in which a chronic allergic airways disease had been induced caused a statistically significant improvement in their symptoms. Moreover, intranasal administration of Cynata’s MSCs completely normalised the symptoms in the experimental animals. Given that the features of this model closely resemble the clinical manifestations of asthma in humans the findings in this study suggest that Cymerus™ MSCs could have a profound effect in the treatment of asthma."
This had a few excited recently, and was also a nice surprise for the long termers news wise
CYP $1 Party, page-124
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $52.99M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 29.5¢ | 27.5¢ | $29.94K | 106.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 10159 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| CYP (ASX) Chart |